Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors

Molecules(2023)10.3390/molecules28217389Source: DataRank Database

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors is a research paper published in Molecules (2023). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.98)OA: goldTopics (65)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Michelle Greenman ORCID,Nicole Pebley ORCID,Levent Mutlu ORCID,Alessandro D. Santin ORCID,Blair McNamara ORCID

Live enrichment

PubMed:37959808 PMC:PMC10650896 OpenAlex:https://openalex.org/W4388228841

NIH Research

Grant: CA-16359

NIH Research

Grant: NIH U01 CA176067-01A1

NIH Research

Grant: 2.0

NCATS NIH HHS

Grant: UL1 TR001863

NCI NIH HHS

Grant: P30 CA016359

NCI NIH HHS

Grant: U01 CA176067

National Institutes of Health

Grant: 1U01CA176067-01A1

Integrated genomic analysis of racial disparities in endometrial cancer

National Institutes of Health

Grant: 2P30CA016359-15

COMPREHENSIVE CANCER CENTER

FWCI

1.98

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1420-3049/28/21/7389/pdf?version=1698899352

publisherhttps://www.mdpi.com/1420-3049/28/21/7389/pdf?version=1698899352

publisherhttps://www.mdpi.com/1420-3049/28/21/7389/pdf

journalhttps://doi.org/10.3390/molecules28217389

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37959808

Fields of Study

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and Immunotoxins03 medical and health sciences0302 clinical medicineFemaleHumansImmunoconjugatesGenital Neoplasms, FemaleAntineoplastic AgentsAntibodies, MonoclonalEpidermal Growth FactorErb-b2 Receptor Tyrosine Kinases

MeSH Terms

Antibodies, MonoclonalAntineoplastic AgentsEpidermal Growth FactorFemaleGenital Neoplasms, FemaleHumansReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesImmunoconjugates

Keywords

Antibody-drug conjugateMonoclonal antibodyMedicineHER2/neuCancer researchEpidermal growth factor receptorTrastuzumabTargeted therapyAntibodyCytotoxic T cellGynecologic cancerDrugDrug deliveryBispecific antibodyTargeted drug deliveryOncologyCancerPharmacologyInternal medicineImmunologyIn vitroBiologyBreast cancerOvarian cancerChemistryerbB2Cervical cancerChemotherapyEndometrial CancerHer2Gynecologic MalignancyAntibody–drug ConjugateImmunoconjugatesEpidermal Growth FactorGenital Neoplasms, FemaleOrganic chemistryAntibodies, MonoclonalAntineoplastic AgentsReviewErb-b2 Receptor Tyrosine KinasesQD241-441HumansFemale

Sustainable Development Goals

SDG 0: Good health and well-being

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors

FAIR Checklist

Authors (5)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)